A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

• Status: RECRUITING
• Trial end date: 2026-04-27

Summary

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then on children (24-59 months of age) and finally to infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.

• Phase: PHASE2

Details

• Lead Sponsor: GlaxoSmithKline
• Collaborators: European & Developing Countries Clinical Trials Partnership; Kwame Nkrumah University of Science and Technology; Pedvac iNTS consortium
• Treatments: diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine; MenACWY; Meningococcal Vaccines; Pneumococcal Vaccines; Poliovirus Vaccine, Inactivated; Rubella Vaccine; Vaccines, Combined; Yellow Fever Vaccine